… in elderly patients with prostate cancer, which … 40 In our phase II study of single-agent
thalidomide … biopsies of the prostate gland (n = 52) or one inguinal node (n = 1). The median …

… -resistant prostate cancer (CRPC), therapies with long response duration remain intangible
due to prostate cancer … in CRPC and we report a phase II trial of RAD001 and bicalutamide. …

… Furthermore, trastuzumab demonstrated inhibition of prostate cancer cell … prostate cancer,
which may respond better to a combination of trastuzumab and a cytotoxic agent in future trials…

… metastasis-directed therapy (MDT) for oligorecurrent prostate cancer (PCa) improves
progression-free survival. We aimed to assess the benefit of MDT in a randomized phase II trial. …

… We conducted a Phase II trial of oral DES in 21 patients. … to early cessation of this Phase II
trial. Eight of 13 patients (62%) … hormone therapy for metastatic prostate cancer. Because it has …

… tea has antitumor effects in patients with prostate carcinoma. This Phase II trial explored
green tea's antineoplastic effects in patients with androgen independent prostate carcinoma. …

… This report describes the results of a randomized phase II trial of docetaxel alone or with
thalidomide in patients with metastatic AIPC. The rationale for combining docetaxel and …

… Prostate cancer is dependent on the recruitment of new blood vessels to grow and …
Phase II trial of thalidomide in patients with metastatic androgen-independent prostate cancer…

… two stages of this phase II trial, as the PSA-defined progression endpoint was no longer
considered in the second stage as a progression criterion, sorafenib in prostate cancer seems to …

… tumor growth in murine prostate cancer xenograft models. We conducted a noncomparative,
randomized, phase II … two doses of oral itraconazole in men with metastatic prostate cancer. …